A Phase 1 Dose Escalation Study of TTI-237 Administered Intravenously (IV) Once Weekly in Subjects With Advanced Malignant Solid Tumors.
Phase 1
18 Years
N/A
18 Years
N/A
Not Enrolling
Both
Tumors, Neoplasms
Both
Tumors, Neoplasms
Trial Information
A Phase 1 Dose Escalation Study of TTI-237 Administered Intravenously (IV) Once Weekly in Subjects With Advanced Malignant Solid Tumors.
Inclusion Criteria:
- Documented diagnosis of malignant solid tumor with measurable disease
- Life expectancy of at least 12 weeks
- ECOG (The Eastern Cooperative Oncology Group scale) performance status of 0, 1, or 2
Exclusion Criteria:
- Recent major surgery, radiation therapy or anti-cancer treatment
- History of any other prior malignancy within the last 5 years
Type of Study:
Interventional
Study Design:
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Educational/Counseling/Training
Outcome Measure:
To determine safety, tolerability, and MTD of TTI-237 - patients are monitored during the duration of their participation on the trial.
Principal Investigator
Medical Monitor
Investigator Role:
Study Director
Investigator Affiliation:
Wyeth is now a wholly owned subsidiary of Pfizer
Authority:
United States: Food and Drug Administration
Study ID:
3162K1-100
NCT ID:
NCT00195325
Start Date:
August 2005
Completion Date:
Related Keywords:
- Tumors
- Neoplasms
- Advanced Malignant Solid Tumors
- Neoplasms
Name | Location |
|---|---|
| Cleveland, Ohio 44195 | |
| Nashville, Tennessee 37203-1632 | |
| Louisville, Kentucky 40207 |
